Literature DB >> 20585991

Clinicopathological determinants of survival after hepatic resection of hepatocellular carcinoma in 97 patients--experience from an Australian hepatobiliary unit.

Terence C Chua1, Akshat Saxena, Francis Chu, Winston Liauw, Jing Zhao, David L Morris.   

Abstract

BACKGROUND: Identification of clinicopathological determinants that predict for risk of recurrence and overall survival after undergoing potentially curative hepatic resection for hepatocellular carcinoma is a strategy towards personalizing therapy to improve outcome. Through evaluation of a center's experience with treatment of a disease, determinants unique to the treated patient cohort may be identified.
METHODS: Ninety-seven patients with hepatocellular carcinoma underwent liver resection. Clinical, treatment, and histopathological variables were collected and evaluated using univariate and multivariate analyses with disease-free survival (DFS) and overall survival (OS) as the endpoints.
RESULTS: The median follow-up period of 19 (range, 1 to 188) months from the time of hepatic resection. The median DFS and OS after resection of HCC were 17 and 41 months, respectively. Five-year overall survival rate was 45%. Eight independent factors associated with disease-free and overall survival were identified through a multivariate analysis. Three factors: Child-Pugh score (DFS p = 0.045, OS p = 0.001), histopathological grade (DFS p < 0.001, OS p < 0.001), and histological diagnosis of cirrhosis (DFS p < 0.001, OS p < 0.001) predicted for both disease-free and overall survival.
CONCLUSION: Integrating the knowledge of identified prognostic factors into clinical decision making may provide a clinicopathological signature that could identify patients at greatest risk of treatment failure such that novel interventions may be applied to improve the survival outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585991     DOI: 10.1007/s11605-010-1277-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  34 in total

1.  Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

Authors:  T Takayama; T Sekine; M Makuuchi; S Yamasaki; T Kosuge; J Yamamoto; K Shimada; M Sakamoto; S Hirohashi; Y Ohashi; T Kakizoe
Journal:  Lancet       Date:  2000-09-02       Impact factor: 79.321

2.  Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

Authors:  W Y Lau; T W Leung; S K Ho; M Chan; D Machin; J Lau; A T Chan; W Yeo; T S Mok; S C Yu; N W Leung; P J Johnson
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

3.  Trends in primary liver cancer.

Authors:  S Deuffic; T Poynard; L Buffat; A J Valleron
Journal:  Lancet       Date:  1998-01-17       Impact factor: 79.321

4.  Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial.

Authors:  E C Lai; C M Lo; S T Fan; C L Liu; J Wong
Journal:  Arch Surg       Date:  1998-02

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

6.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.

Authors:  Eveline Boucher; Stéphane Corbinais; Yan Rolland; Patrick Bourguet; Dominique Guyader; Karim Boudjema; Bernard Meunier; Jean-Luc Raoul
Journal:  Hepatology       Date:  2003-11       Impact factor: 17.425

9.  Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study.

Authors:  Janaki Amin; Dianne O'Connell; Mark Bartlett; Elizabeth Tracey; John Kaldor; Matthew Law; Gregory Dore
Journal:  Aust N Z J Public Health       Date:  2007-10       Impact factor: 2.939

10.  Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.

Authors:  Shinichi Ueno; Masahiko Sakoda; Fumitake Kubo; Kiyokazu Hiwatashi; Taro Tateno; Yoshiro Baba; Susumu Hasegawa; Hirohito Tsubouchi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-03-20
View more
  2 in total

1.  Artificial neural network model for predicting 5-year mortality after surgery for hepatocellular carcinoma: a nationwide study.

Authors:  Hon-Yi Shi; King-Teh Lee; Jhi-Joung Wang; Ding-Ping Sun; Hao-Hsien Lee; Chong-Chi Chiu
Journal:  J Gastrointest Surg       Date:  2012-08-10       Impact factor: 3.452

2.  Is partial hepatectomy a curable treatment option for hepatocellular carcinoma accompanied by cirrhosis? A meta-analysis and cure model analysis.

Authors:  Byungje Bae; Keera Kang; Sung Kyu Song; Chul-Woon Chung; Yongkeun Park
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.